{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:23:19Z","timestamp":1782807799371,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["NIH"],"award-info":[{"award-number":["NIH"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Intratumoral (IT) immunotherapy can stimulate the tumor microenvironment and enhance anti-tumor immunity. We investigated IT delivery of three licensed viral vaccines\u2014Shingrix (VZV shingles), Gardasil-9 (HPV), and Spikevax (SARS-CoV-2)\u2014in prevaccinated mice using the murine tumor model TC-1, which expresses HPV16 oncogenes E6 and E7. Shingrix IT injection often induced tumor regression and resistance to secondary challenge. Injecting a VZV glycoprotein E (gE)-derived MHC-II-restricted peptide with polyI:C also led to durable remission, highlighting the role of gE-specific CD4<jats:sup>+<\/jats:sup> T cells. While Gardasil-9 IT injection alone was ineffective, combining a HPV L1-derived MHC-I-restricted peptide with polyI:C or Shingrix enhanced tumor regression. Both approaches elicited CD8<jats:sup>+<\/jats:sup> T cells against the E7 tumor viral oncoprotein. Tumor microenvironment analysis revealed remodeling of the myeloid compartment, significant induction of IFN-\u03b3, TNF-\u03b1, and CXCL9 and broad gene expression reprograming. In a dual-flank model, IT injection of Shingrix with an MHC-I-restricted E7 tumor-specific peptide eliminated primary and non-injected tumors. Finally, Spikevax IT injection showed modest tumor growth delay, while improved control was observed with a SARS-CoV-2 spike-derived MHC-I-restricted peptide and polyI:C. These results demonstrate the potential of licensed vaccines as promising platforms for IT immunotherapy, either alone or combined with vaccine- or tumor-derived MHC-I-restricted peptide epitopes.<\/jats:p>","DOI":"10.1038\/s41541-025-01131-y","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:20:21Z","timestamp":1745594421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors"],"prefix":"10.1038","volume":"10","author":[{"given":"Shiv K.","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bialkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk Ying","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"\u00c7uburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","volume":"9","author":"L Hammerich","year":"2015","unstructured":"Hammerich, L., Binder, A. & Brody, J. D. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Mol. Oncol. 9, 1966\u20131981 (2015).","journal-title":"Mol. Oncol."},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"e008378","DOI":"10.1136\/jitc-2023-008378","volume":"12","author":"JJ Luke","year":"2024","unstructured":"Luke, J. J. et al. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J. Immunother. Cancer 12, e008378 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"e007198","DOI":"10.1136\/jitc-2023-007198","volume":"11","author":"M Aleynick","year":"2023","unstructured":"Aleynick, M. et al. Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming. J. Immunother. Cancer 11, e007198 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"eaat5025","DOI":"10.1126\/scitranslmed.aat5025","volume":"11","author":"T Shekarian","year":"2019","unstructured":"Shekarian, T. et al. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci. Transl. Med. 11, eaat5025 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1131_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910375","volume":"12","author":"MA Aznar","year":"2020","unstructured":"Aznar, M. A. et al. Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Mol. Med. 12, e10375 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1131_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","volume":"39","author":"G Del Giudice","year":"2018","unstructured":"Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 39, 14\u201321 (2018).","journal-title":"Semin Immunol."},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"SC Eisenbarth","year":"2008","unstructured":"Eisenbarth, S. C., Colegio, O. R., O\u2019Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122\u20131126 (2008).","journal-title":"Nature"},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.1073\/pnas.1104588108","volume":"108","author":"MK MacLeod","year":"2011","unstructured":"MacLeod, M. K. et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc. Natl Acad. Sci. USA 108, 7914\u20137919 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1131_CR11","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.4161\/hv.34408","volume":"10","author":"DM Herrin","year":"2014","unstructured":"Herrin, D. M. et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum. Vaccin Immunother. 10, 3446\u20133454 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"1131_CR12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham, A. L. et al. Immune responses to a recombinant glycoprotein E Herpes Zoster vaccine in adults aged 50 years or older. J. Infect. Dis. 217, 1750\u20131760 (2018).","journal-title":"J. Infect. Dis."},{"key":"1131_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0027-3","volume":"2","author":"M Coccia","year":"2017","unstructured":"Coccia, M. et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity. NPJ Vaccines 2, 25 (2017).","journal-title":"NPJ Vaccines"},{"key":"1131_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"JD Beck","year":"2021","unstructured":"Beck, J. D. et al. mRNA therapeutics in cancer immunotherapy. Mol. Cancer 20, 69 (2021).","journal-title":"Mol. Cancer"},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"1131_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109504","volume":"36","author":"C Bergamaschi","year":"2021","unstructured":"Bergamaschi, C. et al. Systemic IL-15, IFN-gamma, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 36, 109504 (2021).","journal-title":"Cell Rep."},{"key":"1131_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116738119","volume":"119","author":"N Cuburu","year":"2022","unstructured":"Cuburu, N. et al. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proc. Natl Acad. Sci. USA 119, e2116738119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1131_CR20","first-page":"21","volume":"56","author":"KY Lin","year":"1996","unstructured":"Lin, K. Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21\u201326 (1996).","journal-title":"Cancer Res."},{"key":"1131_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/376505","volume":"188","author":"LA Pinto","year":"2003","unstructured":"Pinto, L. A. et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188, 327\u2013338 (2003).","journal-title":"J. Infect. Dis."},{"key":"1131_CR22","doi-asserted-by":"publisher","first-page":"e01641","DOI":"10.1128\/JVI.01641-20","volume":"94","author":"H Voic","year":"2020","unstructured":"Voic, H. et al. Identification and Characterization of CD4(+) T Cell Epitopes after Shingrix Vaccination. J. Virol. 94, e01641\u201320 (2020).","journal-title":"J. Virol."},{"key":"1131_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.4161\/cbt.10.12.13450","volume":"10","author":"YS Cheng","year":"2010","unstructured":"Cheng, Y. S. & Xu, F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol. Ther. 10, 1219\u20131223 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674\u2013687 (2014).","journal-title":"Cancer Discov."},{"key":"1131_CR25","doi-asserted-by":"publisher","first-page":"e001224","DOI":"10.1136\/jitc-2020-001224","volume":"8","author":"H Sultan","year":"2020","unstructured":"Sultan, H. et al. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J. Immunother. Cancer 8, e001224 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","volume":"7","author":"MA Aznar","year":"2019","unstructured":"Aznar, M. A. et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J. Immunother. Cancer 7, 116 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0264-410X(96)00228-9","volume":"15","author":"M Garcia-Valcarcel","year":"1997","unstructured":"Garcia-Valcarcel, M., Fowler, W. J., Harper, D. R., Jeffries, D. J. & Layton, G. T. Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE). Vaccine 15, 709\u2013719 (1997).","journal-title":"Vaccine"},{"key":"1131_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1131_CR29","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 383, 2427\u20132438 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1131_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint, S. et al. Intratumoral delivery of TriMix mRNA results in t-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146\u2013156 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1131_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.virol.2005.01.050","volume":"335","author":"Y Zhi","year":"2005","unstructured":"Zhi, Y. et al. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 335, 34\u201345 (2005).","journal-title":"Virology"},{"key":"1131_CR33","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.4049\/jimmunol.1402256","volume":"194","author":"LK Mackay","year":"2015","unstructured":"Mackay, L. K. et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J. Immunol. 194, 2059\u20132063 (2015).","journal-title":"J. Immunol."},{"key":"1131_CR34","doi-asserted-by":"publisher","first-page":"1794424","DOI":"10.1080\/2162402X.2020.1794424","volume":"9","author":"S Gujar","year":"2020","unstructured":"Gujar, S., Pol, J. G., Kim, Y. & Kroemer, G. Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. Oncoimmunology 9, 1794424 (2020).","journal-title":"Oncoimmunology"},{"key":"1131_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102331","volume":"35","author":"AE Schuind","year":"2023","unstructured":"Schuind, A. E. et al. State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop. Prev. Med Rep. 35, 102331 (2023).","journal-title":"Prev. Med Rep."},{"key":"1131_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22088-1","volume":"12","author":"MC Brown","year":"2021","unstructured":"Brown, M. C. et al. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat. Commun. 12, 1858 (2021).","journal-title":"Nat. Commun."},{"key":"1131_CR38","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/eji.200425547","volume":"35","author":"P Lenz","year":"2005","unstructured":"Lenz, P., Lowy, D. R. & Schiller, J. T. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol. 35, 1548\u20131556 (2005).","journal-title":"Eur. J. Immunol."},{"key":"1131_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1131_CR40","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"1131_CR41","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1084\/jem.20081210","volume":"205","author":"T Saito","year":"2008","unstructured":"Saito, T. & Gale, M. Jr Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 205, 1523\u20131527 (2008).","journal-title":"J. Exp. Med."},{"key":"1131_CR42","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.smim.2020.101414","volume":"49","author":"H Sultan","year":"2020","unstructured":"Sultan, H., Salazar, A. M. & Celis, E. Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol. 49, 101414 (2020).","journal-title":"Semin Immunol."},{"key":"1131_CR43","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","volume":"185","author":"F Baharom","year":"2022","unstructured":"Baharom, F. et al. Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment. Cell 185, 4317\u20134332.e4315 (2022).","journal-title":"Cell"},{"key":"1131_CR44","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn, D. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432\u20131447.e1417 (2023).","journal-title":"Cell"},{"key":"1131_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature11824","volume":"494","author":"H Braumuller","year":"2013","unstructured":"Braumuller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361\u2013365 (2013).","journal-title":"Nature"},{"key":"1131_CR46","doi-asserted-by":"publisher","first-page":"eaaz7548","DOI":"10.1126\/science.aaz7548","volume":"368","author":"Z Zhou","year":"2020","unstructured":"Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548 (2020).","journal-title":"Science"},{"key":"1131_CR47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","volume":"95","author":"HL Greenstone","year":"1998","unstructured":"Greenstone, H. L. et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95, 1800\u20131805 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1131_CR48","doi-asserted-by":"publisher","first-page":"e004464","DOI":"10.1136\/jitc-2021-004464","volume":"10","author":"C Groeneveldt","year":"2022","unstructured":"Groeneveldt, C. et al. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy. J. Immunother. Cancer 10, e004464 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606805","volume":"11","author":"C Bosteels","year":"2020","unstructured":"Bosteels, C. et al. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01. Front Immunol. 11, 606805 (2020).","journal-title":"Front Immunol."},{"key":"1131_CR50","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/mt.2014.133","volume":"22","author":"LA Brito","year":"2014","unstructured":"Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22, 2118\u20132129 (2014).","journal-title":"Mol. Ther."},{"key":"1131_CR51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/imm.12505","volume":"146","author":"S Lazzaro","year":"2015","unstructured":"Lazzaro, S. et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology 146, 312\u2013326 (2015).","journal-title":"Immunology"},{"key":"1131_CR52","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang, F. et al. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol. Ther. 25, 2635\u20132647 (2017).","journal-title":"Mol. Ther."},{"key":"1131_CR53","doi-asserted-by":"publisher","first-page":"e008148","DOI":"10.1136\/jitc-2023-008148","volume":"12","author":"J Tijtgat","year":"2024","unstructured":"Tijtgat, J. et al. Intratumoral administration of the immunologic adjuvant AS01(B) in combination with autologous CD1c (BDCA-1)(+)\/CD141 (BDCA-3)(+) myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. J. Immunother. Cancer 12, e008148 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1131_CR54","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamadermatol.2018.1748","volume":"154","author":"AJ Nichols","year":"2018","unstructured":"Nichols, A. J. et al. Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas. JAMA Dermatol 154, 927\u2013930 (2018).","journal-title":"JAMA Dermatol"},{"key":"1131_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky045","volume":"2","author":"S de Sanjose","year":"2018","unstructured":"de Sanjose, S. et al. Burden of Human Papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58. JNCI Cancer Spectr. 2, pky045 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"1131_CR56","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/cncr.30588","volume":"123","author":"TA Berman","year":"2017","unstructured":"Berman, T. A. & Schiller, J. T. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer 123, 2219\u20132229 (2017).","journal-title":"Cancer"},{"key":"1131_CR57","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst, H., Clifford, G. M., Nascimento, M. C., Madeleine, M. M. & Franceschi, S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J. Cancer 124, 1626\u20131636 (2009).","journal-title":"Int J. Cancer"},{"key":"1131_CR58","doi-asserted-by":"publisher","first-page":"2396710","DOI":"10.1080\/21645515.2024.2396710","volume":"20","author":"R Liu","year":"2024","unstructured":"Liu, R., He, X., Bao, W. & Li, Z. Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: a review. Hum. Vaccin Immunother. 20, 2396710 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"1131_CR59","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00262-019-02357-1","volume":"68","author":"E Ishida","year":"2019","unstructured":"Ishida, E. et al. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunol. Immunother. 68, 1273\u20131286 (2019).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01131-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T16:02:46Z","timestamp":1745596966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01131-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01131-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosure of Potential Conflicts of Interest In accordance with the NIH policies and our ethical obligations as researchers, we report that S.K.S., L.B., L.B., J.T.S. and N.C. are named on a patent application that describe the use of antiviral vaccine antigens for cancer immunotherapy. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}